Bioline Rx Ltd ADR (NASDAQ:BLRX) traded at $5.25 at close of the session on Friday, May 30 and made an upward move of 38.49% on its previous day’s price.
Bioline Rx Ltd ADR has a market cap of $19.53 million and is expected to release its quarterly earnings report in July.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 661.33k, with a low of 450k and a high of 924k. The median projection represents growth adding up to -87.74% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 2.58M, or -91.07% down from figures reported last year.
On the other hand, looking at the outlook for the BLRX stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of 50% Sell.
Based on estimates by 1 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Bioline Rx Ltd ADR (BLRX) stock as a Hold, while 1 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 50.71% off its SMA20 and 64.18% from its 50-day simple moving average. The RSI (14) is pointing at 84.79 while the volatility over the past week is 15.75% and jumps to 8.03% over the past one month. The beta value is 1.13, while the average true range (ATR) is currently pointing at 0.53.
